Flu Vaccine Now Available Across San Diego

San Diego, California - The flu vaccine is here.

And now that the influenza vaccine is readily available across the region, the County Health and Human Services Agency is encouraging the public to get vaccinated.

NIH launches initiative to accelerate genetic therapies to cure sickle cell disease

Washington, DC - The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease, a group of inherited blood disorders affecting at least 100,000 people in the United States and 20 million worldwide. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.

Avoid Carbon Monoxide poisoning and other dangers after a storm makes landfall

Washington, DC - Hurricanes can cause dangerous and destructive high winds, flooding, heavy rain, and storm surges. Carbon monoxide poisoning and driving through floodwaters cause injury and death after storms.

FDA provides update on its ongoing investigation into valsartan products

Washington, DC - The U.S. Food and Drug Administration is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recall of several drug products containing the active pharmaceutical ingredient (API) valsartan, used to treat high blood pressure and heart failure.

Infant Deaths Decline in San Diego

San Diego, California - The infant mortality rate in San Diego County has declined in the last 16 years and is now lower than it is in the state and the nation.

FDA approves new kind of treatment for hairy cell leukemia

Washington, DC - The U.S. Food and Drug Administration approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.